POA Pharma GmbH, a pharmaceutical company based in Sprockhövel, successfully ran its Medical Nutrition Scholarship for the second year. This year, the scholarship extended the applicant pool to Austria and the German Market. The award, which was created by POA Pharma’s parent company, Galen Ltd, aims to support people across Europe with metabolic disorders, such as Phenylketonuria (PKU) and Tyrosinemia (TYR), in achieving their career goals through further education, training and development courses, or apprenticeships.

POA Pharma GmbH has announced the winners of its Medical Nutrition scholarship for 2024 as Milena Krennmayr and Florian Mettenborg. As part of the scholarship prize, Milena and Florian will receive grant of up to €2,500 to support their studies/training courses and electronic teaching aids up to a value of €2,000.

Milena, Austrian Scholarship winner is achieving a master’s degree in biotechnology, has noted, “The scholarship allows me to concentrate on my master’s degree in biotechnology. By graduating with good grades, I can get closer to my goal of working in medical research or pharmaceutical development. It also allows me to eat a balanced, high-quality diet and have enough time for leisure and sport.”

Florian, German Scholarship winner is completing a masters in mechatronics engineering has stated, “PKU is a constant companion in my life, but it should not determine my life. By living with the diet, my goals are achievable. I am happy that POA Pharma is supporting me on this path.

The scholarship gives me the chance to concentrate fully on my training as a master mechatronics engineer for

agricultural and construction machinery. With the financial support, it is easier for me to pay the course fees and my living expenses during the full-time course.

The technology package is also a good support for mastering the digital requirements. I would like to encourage other people with PKU to follow their path.”

Congratulations to the 2024 Medical Nutrition Winners. If you would like to find out more about POA Pharma GmbH and its offering in the German market, including its latest product PKU EASY Microtabs Plus, visit: www.poapharma.de

# ENDS #

About POA Pharma GmbH

POA Pharma GmbH focuses on the distribution, marketing, and commercialisation of proprietary, generic, and rare disease products, bringing German patients selected products and services of POA Pharma Scandinavia AB.

Founded in 2023, it is committed to doing all it can to improve the lives and benefit the health of all generations affected by a variety of diseases.

POA Pharma GmbH benefits from being part of the wider POA Pharma network, providing the resources to help deliver high quality products and services to German patients.

Based in Copenhagen, POA Pharma Scandinavia AB, the parent company of POA Pharma GmbH, works every day to be of value to patients with inborn metabolic diseases (IMDs) and to their caregivers, offering POA products for Phenylketonuria (PKU) as well as for several other IMDs, which are currently available in the UK, Sweden, Norway, Denmark and Finland and the USA.

POA Pharma is part of Galen Limited, a privately owned company established in 1968, with global headquarters in Craigavon, Northern Ireland, and commercial operations based in the UK, Ireland, the Nordics, Europe, and the USA. With global partners in every continent, it is positioned to distribute products worldwide.

Galen Limited was founded in Northern Ireland by the late Sir Allen McClay (d. 2010), the revered philanthropist and entrepreneur, and has since become the proud founding member of the Almac Group

With 6600+ employees and 18 facilities globally, the Almac Group is now owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health.